Precision medicine for large/giant congenital nevus and melanoma
Part of Cancer, Skin clinical trials.
This trial uses a precision medicine approach for people with melanoma. It studies how volatile organic compounds (substances your body releases) might help guide treatment for stage II, III, or IV melanoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with melanoma (stage II, III, or IV) confirmed by a biopsy.
- You must be willing to sign an informed consent form.
- You must not have other cancers or chronic conditions like diabetes or asthma that could affect the study's measurements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using precision medicine to better understand and treat melanoma. Patients with a confirmed melanoma diagnosis can join, helping doctors learn more about the disease and improve care.
This study looks at how certain birthmarks (nevi) change over time and might turn into melanoma. By studying tissue samples, researchers hope to better understand this process.
This study looks at skin spots that might be unusual moles or early melanoma using a special microscope that sees deep into the skin. It aims to match these microscope images with genetic information to better understand these spots.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
This trial studies a very sensitive blood test to detect melanoma-related genetic changes in people with BRAF V600E. It may help track the disease more closely and guide care in advanced or high-risk situations.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.